Jeff Cottrell, Ph.D.

Jeff Cottrell is director of translational research at the Stanley Center for Psychiatric Research at the Broad Institute. He leads a group with diverse expertise focused on translating discoveries of the genetics of psychiatric disease into research programs for the development of novel, mechanism-based treatments for these disorders. His group is focused on multiple aspects of therapeutic discovery: 1) the identification of new targets through a deep understanding of the role of disease-linked genes in neuronal biochemical signaling, 2) the development of high-throughput neuron-based assays, and 3) the implementation of psychiatric disease drug discovery programs for projects from across the Stanley Center, through co-leading a multidisciplinary therapeutics team.

Cottrell came to the Broad Institute in June 2015 after 11 years at Galenea, a biotechnology company focused on therapeutics for CNS disorders. At Galenea, he pioneered the development of high-throughput screening assays of synaptic transmission and their implementation for multiple drug discovery programs for neurodegenerative and psychiatric diseases. Cottrell has 20 years of experience in studying synapses and their dysfunction in disease and has demonstrated unique creativity throughout his career in translating these findings into novel approaches for therapeutic development. He holds a Ph.D. in neuroscience from MIT and an A.B. in psychology from Harvard University.

Contact Jeff Cottrell via email at cottrell@broadinstitute.org.